| GTO ID | GTC2212 |
| Trial ID |
NCT04133636
|
| Disease |
Multiple Myeloma
|
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Carvykti|Ciltacabtagene Autoleucel|Cilta-cel|JNJ-68284528 |
| Co-treatment | BsAb |
| Location approved | US, EU, UK, Japan, Australia, Canada |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma |
| Year | 2019 |
| Country | Belgium|France|Germany|Israel|Netherlands|Saudi Arabia|Spain|United States |
| Company sponsor | Janssen Research & Development, LLC |
| Other ID(s) | CR108581|2018-004124-10|68284528MMY2003 |